GlassScriptPhysician profile
Lyla Rose Masters
NPI 1225327323
$21,994.19
in general payments reported to CMS, 2019-2025
48 companies · $6,182 in 2025
The $6,182 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,437 · 2022: $3,657 · 2023: $4,253 · 2024: $4,465 · 2025: $6,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $1,740 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,905.58 |
| Consulting Fee | $1,740.00 |
| Education | $254.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,965.39 | 2021-2025 | Otezla, Enbrel, Krystexxa |
| Janssen Biotech, INC. | $3,824.92 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,478.66 | 2021-2025 | |
| Pfizer INC. | $1,943.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,152.10 | 2022-2025 | Saphnelo, Evusheld |
| Ucb, INC. | $1,100.48 | 2021-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $949.50 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $794.76 | 2021-2024 | Taltz, Zepbound |
| Ani Pharmaceuticals, INC. | $707.26 | 2022-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $657.43 | 2021-2025 | Actemra, Rituxan, Gazyva |
| Novartis Pharmaceuticals Corporation | $653.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $470.43 | 2021-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $435.06 | 2022-2025 | Acthar |
| Genzyme Corporation | $322.19 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $306.09 | 2021-2025 | Strensiq |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $284.06 | 2021-2024 | Lupkynis |
| Organon LLC | $207.34 | 2023-2025 | Renflexis, Hadlima |
| Hospira, INC. | $173.01 | 2022-2025 | |
| Indivior INC. | $150.02 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $130.05 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $108.36 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.49 | 2021-2023 | Cyltezo, Ofev |
| Fresenius Kabi USA, LLC | $94.85 | 2023-2025 | Idacio |
| Sandoz INC. | $75.16 | 2024 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $73.66 | 2022 | |
| Grifols USA, LLC | $71.41 | 2023-2024 | Gamunex-C |
| Ultragenyx Pharmaceutical INC. | $61.66 | 2021-2022 | |
| Invivyd INC | $57.17 | 2025 | Pemgarda |
| Collegium Pharmaceutical, INC. | $56.95 | 2021-2023 | Xtampza |
| Tersera Therapeutics LLC | $53.35 | 2025 | Quzyttir |
| Novo Nordisk INC | $51.83 | 2023-2024 | Wegovy, Saxenda |
| Radius Health, INC. | $50.79 | 2024-2025 | Tymlos |
| Sobi, INC | $45.58 | 2023 | |
| Mylan Institutional INC. | $44.45 | 2023 | Hulio |
| Kiniksa Pharmaceuticals International, Plc | $43.23 | 2024 | Arcalyst |
| Horizon Therapeutics Plc | $38.11 | 2021-2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $35.84 | 2022-2023 | Quviviq |
| Alnylam Pharmaceuticals INC. | $25.31 | 2022 | |
| Recordati_rare_diseases_inc. | $22.26 | 2023 | Sylvant |
| Teva Pharmaceuticals USA, INC. | $21.91 | 2024 | Simlandi |
| Vertex Pharmaceuticals Incorporated | $21.59 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $19.27 | 2023 | Arcalyst |
| Celltrion USA INC. | $18.68 | 2023 | Yuflyma |
| Octapharma USA, INC. | $18.45 | 2024 | Octagam Immune Globulin (Human) |
| Eisai INC. | $18.35 | 2025 | |
| Almatica Pharma LLC | $17.81 | 2025 | Teriparatide |
| Kyowa Kirin, INC. | $17.76 | 2024 | Crysvita |
| Tonix Medicines, INC. | $16.57 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyla Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.